These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34820969)

  • 1. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study.
    Narcisi A; Valenti M; Cortese A; Toso F; Pavia G; Gargiulo L; Borroni R; Costanzo A
    Dermatol Ther; 2022 Feb; 35(2):e15228. PubMed ID: 34820969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study.
    Megna M; Ruggiero A; Tommasino N; Brescia C; Martora F; Cacciapuoti S; Potestio L
    Clin Cosmet Investig Dermatol; 2024; 17():1037-1042. PubMed ID: 38737943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.
    Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G
    Dermatol Ther; 2022 Jul; 35(7):e15524. PubMed ID: 35439341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany.
    Nyholm N; Schnack H; Danø A; Skowron F
    Curr Med Res Opin; 2023 Jun; 39(6):833-842. PubMed ID: 37203343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective study.
    Megna M; Fabbrocini G; Ruggiero A; Cinelli E
    Dermatol Ther; 2020 Nov; 33(6):e14144. PubMed ID: 32761740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study.
    Megna M; Ruggiero A; Martora F; Vallone Y; Guerrasio G; Potestio L
    J Clin Med; 2024 May; 13(9):. PubMed ID: 38731220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
    Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
    Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study.
    Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G
    J Dermatolog Treat; 2022 Aug; 33(5):2560-2564. PubMed ID: 35098859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
    Mastorino L; Dapavo P; Susca S; Cariti C; Siliquini N; Verrone A; Stroppiana E; Ortoncelli M; Quaglino P; Ribero S
    J Dtsch Dermatol Ges; 2024 Jan; 22(1):34-42. PubMed ID: 37926830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics and small molecules in patients with scalp psoriasis: a systematic review.
    Alsenaid A; Ezmerli M; Srour J; Heppt M; Illigens BM; Prinz JC
    J Dermatolog Treat; 2022 Feb; 33(1):473-482. PubMed ID: 32406275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Translated article] Comparing the Use of Topical Therapy Along with Anti-IL-17 and Anti-IL-23 to Treat Moderate-to-Severe Psoriasis in the Routine Clinical Practice.
    Berenguer-Ruiz S; Romero-Dávila M; Aparicio-Domínguez M; Olivares-Guerrero M; Daudén E; Llamas-Velasco M
    Actas Dermosifiliogr; 2024; 115(7):T647-T653. PubMed ID: 38815679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials.
    Potestio L; Martora F; Lauletta G; Vallone Y; Battista T; Megna M
    Clin Cosmet Investig Dermatol; 2024; 17():829-842. PubMed ID: 38616886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasis and the TNF/IL23/IL17 axis.
    Furue K; Ito T; Tsuji G; Kadono T; Furue M
    G Ital Dermatol Venereol; 2019 Aug; 154(4):418-424. PubMed ID: 30648836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience.
    Bonifati C; Morrone A; Cristaudo A; Graceffa D
    Dermatol Ther; 2021 Jan; 34(1):e14584. PubMed ID: 33236471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors.
    Mastorino L; Susca S; Cariti C; Verrone A; Stroppiana E; Ortoncelli M; Dapavo P; Ribero S; Quaglino P
    Exp Dermatol; 2023 Dec; 32(12):2187-2188. PubMed ID: 36541075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.